Assembly Biosciences

Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.

Assembly Biosciences headquartered in United States, North America, operates in the Biotechnology, Health Care sector. The company focuses on Biotechnology and has secured $10.8B in funding across 32 round(s). With a team of 51-100 employees, Assembly Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Assembly Biosciences, raised $12.6M. Discover more about their projects, partnerships, and impact on our platform.